Avadel gains for a second day as analysts see it prevailing in case vs Jazz/FDA
Seeking Alpha News (Mon, 13-May 3:34 PM ET)
TipRanks (Mon, 13-May 8:01 AM ET)
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results
Globe Newswire (Wed, 8-May 7:00 AM ET)
Globe Newswire (Wed, 1-May 8:00 AM ET)
Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
Globe Newswire (Mon, 1-Apr 8:00 AM ET)
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Globe Newswire (Tue, 5-Mar 8:00 AM ET)
Avadel Pharmaceuticals Issues Statement On Patent Litigation
Globe Newswire (Mon, 4-Mar 3:37 PM ET)
Globe Newswire (Mon, 4-Mar 6:30 AM ET)
Globe Newswire (Mon, 26-Feb 8:00 AM ET)
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
Avadel Pharmaceuticals PLC - Ordinary Share trades on the NASDAQ stock market under the symbol AVDL.
As of May 16, 2024, AVDL stock price declined to $15.90 with 10,080 million shares trading.
AVDL has a beta of 1.14, meaning it tends to be more sensitive to market movements. AVDL has a correlation of 0.07 to the broad based SPY ETF.
AVDL has a market cap of $1.53 billion. This is considered a Small Cap stock.
Last quarter Avadel Pharmaceuticals PLC - Ordinary Share reported $27 million in Revenue and -$.30 earnings per share. This beat revenue expectation by $508,000 and missed earnings estimates by -$.09.
In the last 3 years, AVDL stock traded as high as $19.09 and as low as $1.05.
The top ETF exchange traded funds that AVDL belongs to (by Net Assets): ONEQ, GWX, AADR, APIE, IBRN.
AVDL has underperformed the market in the last year with a price return of +9.6% while the SPY ETF gained +30.0%. However, in the short term, AVDL had mixed performance relative to the market. It has outperformed in the last 3 months, returning +12.0% vs +5.9% return in SPY. But in the last 2 weeks, AVDL shares have been beat by the market, returning -13.2% compared to an SPY return of +5.9%.
AVDL support price is $15.44 and resistance is $16.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVDL stock will trade within this expected range on the day.